Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cellectar Biosciences, Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University of Florida
Endeavor Biomedicines, Inc.
Emory University
Eli Lilly and Company
Milton S. Hershey Medical Center
Children's Oncology Group
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
USWM, LLC (dba US WorldMeds)
Baylor College of Medicine
National Cancer Institute (NCI)
Baylor College of Medicine
GlaxoSmithKline
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
Var2 Pharmaceuticals
Emory University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Seattle Children's Hospital
Seattle Children's Hospital
St. Jude Children's Research Hospital
GlaxoSmithKline
St. Jude Children's Research Hospital
Milton S. Hershey Medical Center
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
University of Wisconsin, Madison
UNC Lineberger Comprehensive Cancer Center
Nationwide Children's Hospital
Instituto do Cancer do Estado de São Paulo
Medical College of Wisconsin
Stanford University
Bambino Gesù Hospital and Research Institute
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Children's National Research Institute
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Emory University
National Institutes of Health Clinical Center (CC)
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Bayer